AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard of care for patients with BRCA mutations1 Results demonstrate a delay in disease progression and an early trend toward improved overall survival with the niraparib and abiraterone acetate regimen versus standard of care in the treatment of mHSPC1 BEERSE, Belgium, Jan. 30, 2026 (GLOBE NEWSWIRE) ...

Core Insights - Nutriband Inc. provided an update on key milestones and discussions from the Annual Shareholders Meeting held on January 24, 2026, in Orlando, Florida [1] Group 1: Leadership Changes - Two new directors were added to the board: Alessandro Puddu, an Italian Chartered Accountant with over 10 years of experience in audit and corporate advisory [2][3][5], and Viorica Carlig, a senior executive with over a decade of leadership experience in service-based companies and a Ph.D. in Economics [6] Group 2: Product Development - Nutriband is focusing on the development of its AVERSA™ FENTANYL product, with significant milestones including a strengthened collaboration with Kindeva for product development and a granted patent in Macao [9] - The company completed the commercial manufacturing process scale-up for AVERSA™ FENTANYL and issued a new US patent expanding its intellectual property protection [9] - A Type C meeting was held with the US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL [9] - Nutriband filed a new provisional patent application covering improved aversive formulations and initiated the development of a worldwide commercial brand name for AVERSA™ FENTANYL [9] Group 3: Financial Updates - The company is in the process of finalizing the sale of its Pocono subsidiary, with a nonrefundable penalty of $10,000 per week collected, totaling $30,000 so far [10] - A complaint was filed with FINRA regarding suspected naked short selling on behalf of shareholders [11] - The company reminded shareholders that warrants issued during its NASDAQ uplisting will expire on October 1, 2026, with 91,090 warrants set to expire at a strike price of $6.43, totaling $5,856,112 if exercised [12] Group 4: Technology Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse and misuse, with a broad intellectual property portfolio covering multiple countries [13][14]

Core Insights - Tonix Pharmaceuticals has presented data showing that TONMYA significantly reduces fibromyalgia pain compared to placebo in a Phase 3 study, indicating its potential as an effective non-opioid treatment for this chronic pain disorder [1][2][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company that markets TONMYA™, the first new prescription medicine approved for fibromyalgia in over 15 years [4]. - The company also has a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [5]. Product Details - TONMYA is a sublingual formulation designed for bedtime dosing, which bypasses first-pass metabolism, optimizing drug exposure during sleep and minimizing daytime exposure to its active metabolite [2][3]. - The Phase 3 RESILIENT trial involved 456 participants and demonstrated a statistically significant reduction in weekly average pain scores at Week 14 (p<0.0001) with an effect size of 0.38, along with improvements in sleep disturbance, fatigue, and other fibromyalgia symptoms [2][3]. Market Need - Fibromyalgia affects over 10 million adults in the U.S., and there is a clear demand for effective non-opioid alternatives as current treatments often have tolerability issues and side effects [2][3].

格隆汇1月30日丨上海莱士(002252.SZ)公布，全资子公司同路生物制药有限公司（"同路生物"）于近期 收到国家药品监督管理局签发的《药品注册证书》，药品名称：人纤维蛋白原。人纤维蛋白原系由健康 人血浆，经分离、提纯，并经病毒去除和灭活处理、冻干制成。同路生物本产品适应症为先天性纤维蛋 白原减少或缺乏症。 ...

Core Insights - The 2025 Innovation Summit, hosted by Economic Observer, focused on themes such as artificial intelligence, digital transformation, robotics, and biomedicine, gathering entrepreneurs, scholars, and industry leaders to share cutting-edge developments and innovative practices [1] - China is entering a new phase of global industrial competition characterized by "innovation racing and cluster breakthroughs," with "new quality productivity" reshaping traditional growth paths through advancements in AI, semiconductor technology, aerospace economy, robotics, and biomedicine [1] - The summit highlighted 20 leading companies recognized for their technological advancements and contributions to industry ecosystems, serving as benchmarks for innovation and value realization during the 14th Five-Year Plan period [1] Industry Highlights - The development of new quality productivity is transitioning from single-point technological breakthroughs to deep integration within industrial scenarios, emphasizing the need for solid innovative practices and implementable development paradigms [1] - The summit introduced the "Qianxing List" featuring outstanding innovative enterprises and benchmark practices, showcasing the industry's core strengths and innovative capabilities [1] Company Case Studies - Bai Li Tian Heng's transformation practice was highlighted as a significant case [3] - The Iza-Bren dual-antibody ADC research project aims to fill treatment gaps for multiple tumor types, leading global breakthroughs in innovative oncology drugs [4] - Huawei's business attribute-based monitoring solution for the securities industry was presented as a key innovation [5] - The Wangdong health management solution case from Wenzhou People's Hospital was showcased by Huawei [6] - Kingsoft Office's WPS 365 smart education platform was recognized for empowering digital upgrades in higher education [7] - JD Technology's AI innovation practices in government services were also featured [7] - The establishment of a commercial production line EBR system by iFlytek aims to empower high-quality development in the biomedicine industry through digital upgrades [8] - iFlytek's Starfire large model demonstrates full-scenario penetration and value creation [9] - Kuaishou Technology's AI-assisted interactive comics address pain points in AI companionship, creating a new upgraded paradigm for comic experiences [10] - Ant Group's technological breakthroughs and commercialization practices in AI were highlighted [11] - Qianshi Technology's Lingguang App leads a new paradigm for multimodal AI assistants [12] - Schneider Electric's WYLON® large model integrated machine showcases innovative practices [13] - Yiling Pharmaceutical's predictive maintenance system based on multimodal large models demonstrates technological breakthroughs and scalable applications [14]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals' quarterly revenue is $3.79 billion, versus $3.79 billion a year earlier, according to data from Benzinga Pro.On Dec. 1, Regeneron Pharmaceuticals and Tessera Th ...

Earnings Results - Regeneron Pharmaceuticals is set to release its fourth-quarter earnings results on January 30, with analysts expecting earnings of $10.74 per share, a decrease from $12.07 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $3.79 billion, unchanged from the previous year [1] Collaboration Announcement - On December 1, Regeneron Pharmaceuticals announced a global collaboration with Tessera Therapeutics to develop and commercialize TSRA-196 [2] - Following the announcement, Regeneron Pharmaceuticals shares experienced a slight decline of 0.2%, closing at $749.44 [2] Analyst Ratings - Benzinga provides access to the latest analyst ratings for Regeneron Pharmaceuticals, allowing readers to sort by various criteria such as stock ticker and rating change [2]

Core Viewpoint - Danish pharmaceutical company Novo Nordisk announced that Senior Vice President and head of its business in China, Christine Zhou, will leave the company at the end of March [1] Company Summary - Christine Zhou has been a key figure in Novo Nordisk's operations in China [1] - The departure is significant as it may impact the company's strategic direction and market presence in the Chinese pharmaceutical sector [1]

Industry Overview - The pharmaceutical industry is facing a potential loss of $300 billion, which represents one-sixth of its overall revenue, by 2030 due to a patent cliff [1] - Companies that can adapt quickly will be better positioned to navigate this challenge [1] Company-Specific Insights - Eli Lilly and Novo Nordisk are well-positioned with limited patent exposure and significant earnings from GLP-1 weight loss drugs [2] - Bristol Myers Squibb faces a significant challenge with a projected growth gap of about $38 billion, primarily due to the loss of patent protection for its top drugs, Eliquis and Opdivo, which together account for over half of its earnings [3] - Merck & Co. and Pfizer are also facing substantial gaps of $23 billion and $21 billion, respectively [3] Strategic Responses - Successful companies are employing multi-faceted strategies to mitigate losses, including mergers and acquisitions (M&A) to strengthen their drug pipelines [4] - Beyond M&A, companies are also focusing on delaying patent expirations, exploring new drug development areas, and refocusing efforts to generate growth [5] Johnson & Johnson's Position - Johnson & Johnson is positioning itself as a success story amid the patent cliff, despite facing challenges such as biosimilar competition for its drug Stelara, which could lead to a $15 million revenue gap [6] - The company’s drug Darzalex, with projected sales of almost $18 billion in 2024, will soon encounter its own patent cliff [6] - J&J reported over $24 billion in quarterly sales with a 6% increase in annual sales, surpassing market expectations, and is framing 2025 as a pivotal year for growth [7]

The FTSE 100 Index continued its rally this week and was hovering near its all-time high as market participants reacted to the key earnings by some American companies and Lloyds Bank. Shell and other energy companies are benefiting from the ongoing crude oil price rally because of rising tensions in the Middle East now that Trump has sent a large armada to the region and Iran has warned of a prolonged fight. It was trading at £10,170, a few points below the all-time high of £10,240. This article explores so ...